Real-world efficacy of ribociclib plus aromatase inhibitor/fulvestrant, or endocrine monotherapy, or chemotherapy as first-line treatment in women with HR-positive, HER2-negative locally advanced or metastatic breast cancer: Third interim analysis from the RIBANNA study

Wockel A, Brucker C, Decker T, Falbrede J, Forstbauer H, Gohler T, Hoffmann O, Jackisch C, Janssen J, Kohler A, Ludtke-Heckenkamp K, Luftner D, Marme F, Nusch A, Reimer T, Roos C, Schmidt M, Weide R, Fasching P (2021)

Publication Type: Conference contribution

Publication year: 2021

Journal

Cancer Research American Association for Cancer Research

Publisher: AMER ASSOC CANCER RESEARCH

City/Town: PHILADELPHIA

Conference Proceedings Title: CANCER RESEARCH

DOI: 10.1158/1538-7445.sabcs20-ps10-16

Authors with CRIS profile

Peter Fasching Professur für Translationale Frauenheilkunde und Geburtshilfe

Involved external institutions

Universitätsmedizin Rostock DE Germany (DE) Universitätsklinikum Essen DE Germany (DE) Universitätsklinikum Würzburg DE Germany (DE) Charité - Universitätsmedizin Berlin DE Germany (DE) Medizinische Studiengesellschaft Nord-West GmbH DE Germany (DE) Niels-Stensen-Kliniken GmbH DE Germany (DE) Onkozentrum Dresden/Freiberg DE Germany (DE) Sana Klinikum Offenbach DE Germany (DE) Städtische Kliniken Neuss Lukaskrankenhaus GmbH DE Germany (DE) Johannes Gutenberg-Universität Mainz (JGU) DE Germany (DE) Ruprecht-Karls-Universität Heidelberg DE Germany (DE) Novartis AG CH Switzerland (CH) Paracelsus Medizinische Privatuniversität AT Austria (AT)

How to cite

APA:

Wockel, A., Brucker, C., Decker, T., Falbrede, J., Forstbauer, H., Gohler, T.,... Fasching, P. (2021). Real-world efficacy of ribociclib plus aromatase inhibitor/fulvestrant, or endocrine monotherapy, or chemotherapy as first-line treatment in women with HR-positive, HER2-negative locally advanced or metastatic breast cancer: Third interim analysis from the RIBANNA study. In CANCER RESEARCH. PHILADELPHIA: AMER ASSOC CANCER RESEARCH.

MLA:

Wockel, Achim, et al. "Real-world efficacy of ribociclib plus aromatase inhibitor/fulvestrant, or endocrine monotherapy, or chemotherapy as first-line treatment in women with HR-positive, HER2-negative locally advanced or metastatic breast cancer: Third interim analysis from the RIBANNA study." Proceedings of the CANCER RESEARCH PHILADELPHIA: AMER ASSOC CANCER RESEARCH, 2021.

BibTeX: Download